{"keywords": [{"value": "Mergers, Acquisitions and Divestitures", "rank": "1", "is_major": "N", "name": "subject"}, {"value": "Drugs (Pharmaceuticals)", "rank": "2", "is_major": "N", "name": "subject"}, {"value": "Valeant Pharmaceuticals International Inc", "rank": "3", "is_major": "N", "name": "organizations"}], "headline": {"kicker": "Breakingviews", "content_kicker": "Breakingviews", "main": "As Valeant\u2019s Mergers Slow, Scrutiny Intensifies"}, "byline": {"original": "By ROBERT CYRAN", "person": [{"rank": 1, "role": "reported", "organization": "", "lastname": "CYRAN", "firstname": "Robert"}]}, "web_url": "http://www.nytimes.com/2015/10/23/business/dealbook/as-valeants-mergers-slow-scrutiny-intensifies.html", "source": "The New York Times", "subsection_name": "DealBook", "slideshow_credits": null, "type_of_material": "News", "_id": "56294b7238f0d843c6275d91", "multimedia": [], "pub_date": "2015-10-23T00:00:00Z", "print_page": null, "section_name": "Business Day", "word_count": "411", "blog": [], "news_desk": "Business", "snippet": "When growth through acquisitions dries up, there\u2019s greater focus on the reality of sales and profit. And watchdogs are looking, too.", "document_type": "article", "abstract": null, "lead_paragraph": "When growth through acquisitions dries up, there\u2019s greater focus on the reality of sales and profit. And watchdogs are looking, too."}